17 completed, 14 unknown, 5 terminated, 2 active not recruiting. 42 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 42 | Completed 17, Unknown 14, Terminated 5, Active not recruiting 2, Withdrawn 2, Not yet recruiting 1, Suspended 1 |
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients combination therapy, SOC - COVID-19, SARS-CoV-2 | Not applicable | Not yet recruiting | National Taiwan University Hospital | 40 | 2024-09-21 | 2024-09-25 |
| A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose, Placebo - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 350 | 2023-04-01 | 2023-03-16 |
| Addressing Post-COVID-19 Musculoskeletal Symptoms Multicomponent exercise program, Tele-health primary care rehabilitation program - Telemedicine, Musculoskeletal Disease | Not applicable | Completed | Universidad Europea de Madrid | 62 | 2023-03-20 | 2025-01-27 |
| Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 3200 | 2023-01-04 | 2023-02-28 |
| Virus and Bronchial Epithelium in Children and the Elderly SARS-CoV-2, Adenovirus (AdV), Rhinovirus - SARS-CoV-2 | Not applicable | Unknown | University Hospital, Bordeaux | 200 | 2022-10-28 | 2024-01-25 |
| A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose, Placebo - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 350 | 2022-09-26 | 2023-02-14 |
| A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose, Placebo - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 54 | 2022-09-16 | 2023-02-14 |
| A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose, COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose, Placebo - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 54 | 2022-09-13 | 2023-02-14 |
| The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity, Humoral Immunity - SARS-CoV-2, Safety | Not applicable | Unknown | Zhongnan Hospital | 1000 | 2022-08-13 | 2022-10-12 |
| The Safety and Tolerability of A8G6 COVID-19 Neutralization Antibody Combined With Nasal Spray A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray, A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient - SARS-CoV-2, Prevention | Not applicable | Unknown | The Second Affiliated Hospital of Chongqing Medical University | 108 | 2022-05-01 | 2023-11-13 |
| Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 1) Probiotics daily, Placebo daily - SARS-CoV-2 | Not applicable | Completed | Peking University | 31 | 2022-03-09 | 2022-07-07 |
| Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 2) 1 week placebo(Week 1), 1 week of probiotics(Week 1), 1 week placebo(Week 2) - SARS-CoV-2 | Not applicable | Completed | Peking University | 44 | 2022-02-27 | 2022-11-03 |
| Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region Blood sampling, Gargle sampling, Questionnaire completion - SARS-CoV-2, SARS-CoV-2 (COVID-19) Infection | Not applicable | Completed | The Institute of Molecular and Translational Medicine, Czech Republic | 2484 | 2022-01-18 | 2026-02-04 |
| The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray, Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient - SARS-CoV-2, Prevention | Not applicable | Unknown | The Second Affiliated Hospital of Chongqing Medical University | 72 | 2021-12-17 | 2023-08-04 |
| The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community Rapid antigen testing kit - Covid19, SARS-CoV-2 | Not applicable | Completed | Mahidol University | 70000 | 2021-11-01 | 2023-01-17 |
| Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) Cardiac PET/MRI, Blood Biomarkers - Myocardial Injury, Myocarditis | Not applicable | Active not recruiting | University Health Network, Toronto | 57 | 2021-08-05 | 2026-04-24 |
| Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities Family Risk Messaging, Personal Risk Messaging, Loss Protection - SARS-CoV-2 | Not applicable | Completed | University of Southern California | 2164 | 2021-06-29 | 2024-08-14 |
| The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial Telerehabilitation - Respiratory Failure, Sars-CoV-2 | Not applicable | Unknown | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 100 | 2021-06-12 | 2021-08-16 |
| Risk of SARS-CoV-2 Infection (COVID-19) in a Standing Concert in a Closed Performance Hall Concert - SARS-CoV-2 | Not applicable | Withdrawn | University Hospital, Montpellier | 2021-06-01 | 2021-10-20 | |
| SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector Serological testing - SARS-CoV-2, Covid19 | Not applicable | Active not recruiting | Universitair Ziekenhuis Brussel | 200 | 2021-05-05 | 2025-12-18 |
Showing 20 of 42. Sign in to see all of them.
COVID-19 (25) · Coronavirus Infections (8) · Adenoviridae Infections (1) · Anosmia (1) · Communicable Diseases (1) · Disease (1) · Dyspnea (1) · Health Education (1) · Infections (1) · Lacerations (1) · Lung Diseases, Interstitial (1) · Motor Activity (1) · Multiple Organ Failure (1) · Musculoskeletal Diseases (1) · Myocarditis (1)
Virus Diseases (26) · Coronaviridae Infections (25) · Infections (25) · Lung Diseases (25) · Nidovirales Infections (25) · Pneumonia (25) · Pneumonia, Viral (25) · RNA Virus Infections (25) · Respiratory Tract Diseases (25) · Respiratory Tract Infections (25) · Coronavirus Infections (17) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (4) · Pathologic Processes (3) · Behavior (2)
mRNA Vaccines (4) · Blood Specimen Collection (2) · Blood Cell Count (1) · Body Temperature (1) · COVID-19 Serological Testing (1) · COVID-19 Serotherapy (1) · CVnCoV COVID-19 vaccine (1) · Combined Modality Therapy (1) · Data Collection (1) · Hydrogen (1) · Hydroxychloroquine (1) · Immunity, Cellular (1) · Immunity, Humoral (1) · Leukapheresis (1) · Ritonavir (1)
AIM Vaccine Co., Ltd. (5) · Assistance Publique - Hôpitaux de Paris (2) · Indiana University (2) · NOWDiagnostics, Inc. (2) · Peking University (2) · The Second Affiliated Hospital of Chongqing Medical University (2) · AGIR à Dom (1) · Bispebjerg Hospital (1) · CMC Ambroise Paré (1) · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland (1) · Centre Hospitalier Régional d'Orléans (1) · Centre Scientifique de Monaco (1) · Copenhagen University Hospital, Rigshospitalet (1) · Hospital Italiano de Buenos Aires (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1)
China (9) · United States (9) · France (6) · Belgium (3) · Denmark (2) · Argentina (1) · Canada (1) · Czechia (1) · Hungary (1) · Italy (1) · Monaco (1) · Morocco (1) · Serbia (1) · Spain (1) · Switzerland (1)
Huan Zhou (5) · Qiang Wu (5) · Dazhi Zhang, M.D. (2) · Alexandra K Adams, MD, PhD (1) · Antoine Rousseau, PhD (1) · Berit L. Heitmann, Professor, Ph.D (1) · Beth Cobb (1) · Beth L Cobb (1) · Carolina Guerrieri, Director (1) · Courtney Rowan, MD (1) · David O'Connor, PhD (1) · Dhammika Leshan Wannigama, MD.PhD (1) · Erica Miyazaki, MD (1) · Esteban Nannini, MD (1) · Florencia Otermin, MD (1)
PMID 16940336, PMID 32993779, PMID 33232588, PMID 34013969, PMID 34193503, PMID 34418958, PMID 34819329, PMID 35891471, PMID 36066373, PMID 36734509, PMID 36827328, PMID 37162745, PMID 37258079, PMID 37549192, PMID 37795693, PMID 38088562, PMID 38903523, PMID 39224811, PMID 39247614, PMID 40068080, PMID 40399889, PMID 40983579
P20GM104417 (1), P51OD011106 (1), R33AG057395 (1)